STIMULANT
A-PCYP. LARGE CRYSTAL
alpha -pcyp is a synthetic stimulant drug of the cathinone class developed in the middle of 2019 which has been reported as a novel designer drug. α-pcyp is a substituted homologue of α-PVP, having an cyclohexane replaced the alkyl side chain,regarding t
$ 3.20
VIEW MORE
MDPEP .POWDER
MDPEP is a stimulant of the cath class originally developed in the 1960s,which has been reported as a novel designer drug. It is closely related to the potent stimulant MDPV though with slightly milder effects, and has been used as an alternative in some
$ 1.40
VIEW MORE
NDH .CRYSTAL
NDH (also known as n-isobutyl-hexedrone) is a stimulant research chemical belonging to the cathinone group. isobutyl-hexedrone's stimulation is believed to be caused by its affinity as an NDRI (norepinephrine-dopamine reuptake inhibitor); however, there h
$ 1.40
VIEW MORE
BK-BBDP .LARGE CRYSTAL
β-Keto-3,4-methylenedioxy-alpha-propyl-N-butyl-phenethylamine (N-butylpentylone , BK-BUTYL-K, BK-BBDP) is a stimulant compound developed in the 1960s, which has been reported as a novel designer drug, identified in some samples of powders sold as "BUTYL-
$ 1.40
VIEW MORE
4F-MPH. HCL. POWDER
4-Fluoromethylphenidate (also known as 4-FMPH and 4F-MPH) is a stimulant drug that acts as a higher potency dopamine reuptake inhibitor than the closely related methylphenidate 4-Fluoromethylphenidate was studied further along with of (TMP) to assess th
$ 3.80
VIEW MORE
4-FEA .POWDER
4-Fluoroethamphetamine (also known as 4-FEA) is a novel synthetic ring-substituted fluorinated am compound that produces a mixture of entactogenic and stimulant effects when administered. 4-FEA is structurally related to a series of designer fluorinated s
$ 3.80
VIEW MORE
ISOPROPYLPHENIDATE.HCL.CRYSTAL
ISOPROPYLPHENIDATE (also known as IPH and IPPD) is a piperidine based stimulant RC, closely related to ethylphenidate, but with the ethyl ester replaced by an isopropyl ester. This product is intended for forensic and research purposes.
$ 3.90
VIEW MORE
NEWSLETTER
Subscribe to our email for the latest information